RxDoctor Payments Data

Olga Shabalov, MD

Cardiovascular Disease · Pittsburgh, PANPI 1518962992

Payments from drug & device makers

$4,234in general payments, 2019–2025

Across 257 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$760
  • Novartis$573
  • Amgen$508
  • Amarin Pharma, Inc.$425
  • E.r. Squibb & Sons, L.L.C.$363
  • Pfizer$282
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,19699%
  • Education$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,234 in reported general payments places this provider in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$114,046
Medicare patients
733
Services billed
1,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban691$827,935
EntrestoSacubitril/Valsartan396$498,472
XareltoRivaroxaban155$161,265
JardianceEmpagliflozin129$133,578
Repatha SureclickEvolocumab105$109,176
MultaqDronedarone Hcl37$70,747
Repatha SyringeEvolocumab31$34,554
Metoprolol Succinate1,385$24,758
Rosuvastatin Calcium1,036$18,508
BrilintaTicagrelor20$18,191
Losartan Potassium860$11,300
Diltiazem 24hr Er (Cd)Diltiazem Hcl388$10,625
Atorvastatin Calcium740$10,068
Icosapent Ethyl30$9,705
Praluent PenAlirocumab11$9,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$282$827,935691 claims
NovartisEntresto$573$498,472396 claims
Johnson & JohnsonXarelto$760$161,265155 claims
Boehringer IngelheimJardiance$178$133,578129 claims
Sanofi-aventis U.S. LLCMultaq$218$70,74737 claims
AstraZenecaBrilinta$222$18,19120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →